DE69435137D1 - Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind - Google Patents

Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind

Info

Publication number
DE69435137D1
DE69435137D1 DE69435137T DE69435137T DE69435137D1 DE 69435137 D1 DE69435137 D1 DE 69435137D1 DE 69435137 T DE69435137 T DE 69435137T DE 69435137 T DE69435137 T DE 69435137T DE 69435137 D1 DE69435137 D1 DE 69435137D1
Authority
DE
Germany
Prior art keywords
tgf
beta
muscle cells
production
activators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435137T
Other languages
English (en)
Inventor
David J Grainger
James C Metcalfe
Peter L Weissberg
Paul R Kemp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69435137D1 publication Critical patent/DE69435137D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
DE69435137T 1993-05-13 1994-05-12 Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind Expired - Lifetime DE69435137D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6171493A 1993-05-13 1993-05-13
PCT/US1994/005265 WO1994026303A1 (en) 1993-05-13 1994-05-12 Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells

Publications (1)

Publication Number Publication Date
DE69435137D1 true DE69435137D1 (de) 2008-10-16

Family

ID=22037630

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69435137T Expired - Lifetime DE69435137D1 (de) 1993-05-13 1994-05-12 Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind

Country Status (7)

Country Link
US (7) US5847007A (de)
EP (1) EP0710116B1 (de)
JP (2) JPH08510451A (de)
AT (1) ATE406909T1 (de)
CA (1) CA2162586C (de)
DE (1) DE69435137D1 (de)
WO (1) WO1994026303A1 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) * 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2162586C (en) 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
DE69434617D1 (de) * 1993-11-19 2006-04-06 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
US6359194B1 (en) * 1995-02-10 2002-03-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US20020170077A1 (en) * 1995-02-10 2002-11-14 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US6156500A (en) * 1995-02-10 2000-12-05 Millennium Pharmaceuticals, Inc. Methods for the treatment and diagnosis of cardiovascular disease
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE69637316T2 (de) * 1995-06-07 2008-08-28 Poniard Pharmaceuticals, Inc., Seattle Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
US6099823A (en) * 1996-02-16 2000-08-08 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
EP0904277A4 (de) 1996-02-16 2003-01-22 Millennium Pharm Inc Zusammensetzungen und verfahren zur behandlung und diagnose von kardiovaskulären krankheiten
EP0914094A4 (de) 1996-03-28 2000-03-01 Univ Illinois Materialen und verfahren zur herstellung verbesserter liposomaler mittel
EP1616563A3 (de) 1996-05-24 2006-01-25 Angiotech Pharmaceuticals, Inc. Perivaskuläre Verabreichung anti-angiogener Faktoren zur Behandlung oder Prävention von Gefässerkrankungen
US5836896A (en) * 1996-08-19 1998-11-17 Angiosonics Method of inhibiting restenosis by applying ultrasonic energy
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
ZA985544B (en) * 1997-06-27 1998-12-28 Smithkline Beecham Corp Novel methods
ZA985543B (en) * 1997-06-27 1998-12-28 Smithkline Beecham Corp Novel methods
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
EP1000935A4 (de) * 1997-07-25 2001-03-21 Tsumura & Co Pyridylacrylamid-derivate und arzneimittel gegen nephritis und inhibitoren des transformierenden wachstumsfaktors beta die diese derivate enthalten
US5866561A (en) * 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
TR200001081T2 (tr) * 1997-10-27 2000-10-23 Agouron Pharmaceuticals, Inc. CDKS inhibitörleri olarak ikame edilmiş 4-amino tiyazol-2-il bileşikleri
AU1284999A (en) * 1997-10-28 1999-05-17 Jain, Mukesh (in vitro) differentiation of vascular smooth muscle cells, methods and reagentsrelated thereto
US5962667A (en) * 1997-11-03 1999-10-05 Virginia Commonwealth University Pharmaco-gene delivery in human breast cancer cells
US6165209A (en) * 1997-12-15 2000-12-26 Prolifix Medical, Inc. Vascular stent for reduction of restenosis
EP1039946B1 (de) 1997-12-19 2008-02-13 United States Surgical Corporation Spenderanordnung
JP2001526926A (ja) 1997-12-31 2001-12-25 ファーマソニックス，インコーポレイテッド 血管過形成を抑制するための方法およびシステム
CA2320300A1 (en) 1998-02-10 1999-08-12 Angiosonics Inc. Apparatus and method for inhibiting restenosis by applying ultrasound energy together with drugs
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
CZ300960B6 (cs) 1998-05-07 2009-09-23 The University Of Tennessee Research Corporation Lécivo pro lécení prostatické intraepitelové neoplasie
US6413535B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
KR100293504B1 (ko) 1998-06-05 2001-07-12 김윤 서방형전립선염치료제조성물
AU4435399A (en) 1998-06-11 1999-12-30 Cerus Corporation Inhibiting proliferation of arterial smooth muscle cells
US7393864B2 (en) 1999-02-26 2008-07-01 University Of Iowa Research Foundation Use of ClC3 chloride channel blockers to modulate vascular tone
US7220782B1 (en) 1999-02-26 2007-05-22 University Of Iowa Research Foundation Methods to reduce the sensitivity of endothelially-compromised vascular smooth muscle
WO2001008694A2 (en) * 1999-07-30 2001-02-08 Massachusetts Institute Of Technology Direct arterial infiltration for production of vascular pathology
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20040158317A1 (en) * 2000-07-18 2004-08-12 Pharmasonics, Inc. Coated stent with ultrasound therapy
DE60124285T3 (de) 2000-09-29 2011-03-17 Cordis Corp., Miami Lakes Beschichtete medizinische geräte
AU9463401A (en) 2000-10-16 2002-04-29 Conor Medsystems Inc Expandable medical device for delivery of beneficial agent
US20040204756A1 (en) * 2004-02-11 2004-10-14 Diaz Stephen Hunter Absorbent article with improved liquid acquisition capacity
JP2002236307A (ja) * 2001-02-09 2002-08-23 Asahi Optical Co Ltd ズームストロボ装置
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20040249443A1 (en) * 2001-08-20 2004-12-09 Shanley John F. Expandable medical device for treating cardiac arrhythmias
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7842083B2 (en) * 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
JP3990972B2 (ja) * 2001-11-20 2007-10-17 有限会社 キック 血管再狭窄防止薬及び該防止薬がコーティングされた血管内埋め込み器具
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
JP2006505364A (ja) * 2002-11-08 2006-02-16 コナー　メドシステムズ，　インコーポレイテッド 血管新生因子の局所供給を用いる、慢性全梗塞を処置するための拡張可能な医療装置および方法
KR20130032407A (ko) * 2002-11-08 2013-04-01 코너 메드시스템즈, 엘엘씨 허혈성 상해 후에 조직 손상을 감소시키기 위한 방법 및 장치
US20040142014A1 (en) * 2002-11-08 2004-07-22 Conor Medsystems, Inc. Method and apparatus for reducing tissue damage after ischemic injury
US20040202692A1 (en) * 2003-03-28 2004-10-14 Conor Medsystems, Inc. Implantable medical device and method for in situ selective modulation of agent delivery
AU2004226327A1 (en) 2003-03-28 2004-10-14 Innovational Holdings, Llc Implantable medical device with beneficial agent concentration gradient
US20050010170A1 (en) * 2004-02-11 2005-01-13 Shanley John F Implantable medical device with beneficial agent concentration gradient
US20050100577A1 (en) * 2003-11-10 2005-05-12 Parker Theodore L. Expandable medical device with beneficial agent matrix formed by a multi solvent system
CN1972714B (zh) * 2004-04-06 2012-10-03 诺夫免疫股份有限公司 治疗自身免疫疾病和炎性疾病的方法
US20050287287A1 (en) * 2004-06-24 2005-12-29 Parker Theodore L Methods and systems for loading an implantable medical device with beneficial agent
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
KR101093930B1 (ko) * 2007-09-13 2011-12-13 경북대학교병원 스코파론의 신규 용도
GB2475907A (en) 2009-12-04 2011-06-08 Tcp Innovations Ltd Composition comprising a mixture of clopidogrel and droloxifene
US20140137274A1 (en) * 2011-11-30 2014-05-15 Lsip, Llc Induced malignant stem cells
JP2016512151A (ja) * 2013-03-14 2016-04-25 テレフレックス メディカル インコーポレイテッドＴｅｌｅｆｌｅｘ Ｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 局所薬物送達
US10286116B2 (en) * 2015-04-15 2019-05-14 Mayo Foundation For Medical Education And Research Methods and materials for reducing venous neointimal hyperplasia of an arteriovenous fistula or graft
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33403A (en) * 1861-10-01 Improved scale and weighing apparatus
US32944A (en) * 1861-07-30 Skate
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
NL224562A (de) * 1957-02-05
US3168565A (en) * 1959-11-20 1965-02-02 Richardson Merrell Inc Trifluoromethyl derivatives of amino triarylethanols, -ethanes, and -ethylenes
GB1015787A (en) * 1962-08-03 1966-01-05 Giuseppe Carlo Sigurta Tris-(p-methoxyphenyl)ethylene derivatives
BE637389A (de) * 1962-09-13
US3288806A (en) * 1964-03-23 1966-11-29 Parke Davis & Co Alpha-(aminoethoxyphenyl)-alpha-alkylstilbenes
GB1105787A (en) * 1965-01-25 1968-03-13 Gen Electric Improvements in "recording medium"
US3445473A (en) * 1965-04-10 1969-05-20 Hoechst Ag 3-anilino-thiophene-4-carboxylic acids,esters,and amides
US3634517A (en) * 1968-08-19 1972-01-11 Richardson Merrell Inc Triarylalkenones
US4221785A (en) * 1978-05-30 1980-09-09 Sorenson John R J Anti-inflammatory and anti-ulcer compounds and process
US4070484A (en) * 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
JPS5640710B2 (de) * 1973-01-18 1981-09-22
IT1070993B (it) 1973-12-24 1985-04-02 Bioindustria Spa Derivati del tiofene ad attivita antimicotica e tricomonicida
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4323707A (en) * 1975-10-28 1982-04-06 Eli Lilly And Company Antifertility compounds
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4428963A (en) * 1976-08-23 1984-01-31 Hoffmann-La Roche Inc. Novel thiophene derivatives
CH628628A5 (en) 1976-08-23 1982-03-15 Hoffmann La Roche Process for the preparation of cyclic compounds
US4317915A (en) * 1976-08-23 1982-03-02 Hoffmann-La Roche Inc. Novel thiophene derivatives
US4235988A (en) * 1976-12-13 1980-11-25 Imperial Chemical Industries Limited Delivery means for biologically active agents
US4440754A (en) * 1978-05-30 1984-04-03 Sorenson John R J Anti-inflammatory and anti-ulcer compounds and process
US4239778A (en) * 1978-09-12 1980-12-16 The University Of Illinois Foundation Azaprostanoic acid analogs and their use as inhibitors of platelet aggregation
US4219656A (en) * 1978-10-24 1980-08-26 American Cyanamid Company 3,4-Disubstituted thiophenes
ATE1418T1 (de) * 1979-05-15 1982-08-15 Imperial Chemical Industries Plc 1-hydrocarbyloxyphenyl-1.2-diphenylalkenderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzung.
US4382143A (en) * 1979-07-23 1983-05-03 American Cyanamid Company Hypolipidemic and antiatherosclerotic novel (monosubstituted-amino)heteroaryl carboxylic acids and analogs
AU532174B2 (en) 1979-08-15 1983-09-22 Stephen James Beveridge Copper chelate compounds
US4487780A (en) * 1979-09-18 1984-12-11 Scheinberg Israel H Method of treatment of rheumatoid arthritis
US4282246A (en) * 1980-03-07 1981-08-04 Pfizer Inc. Antidiabetic furancarboxylic and thiphenecarboxylic acids
US5658927A (en) 1980-03-07 1997-08-19 Research Corporation Technologies Diphenylcyclopropyl analogs
US5324736A (en) * 1980-03-07 1994-06-28 Research Corporation Technologies, Inc. Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents
US5098903A (en) * 1980-03-07 1992-03-24 Board Of Regents Of The University Of Oklahoma Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents
US5658951A (en) 1980-03-07 1997-08-19 Research Corporation Technologies Diphenylcyclopropyl analogs
US4879315A (en) * 1982-03-30 1989-11-07 The Board Of Regents For The University Of Oklahoma Cyclopropyl analogs as anti-estrogenic, anti-tumor and female fertility agents
ATE4775T1 (de) * 1980-04-29 1983-10-15 Blendax-Werke R. Schneider Gmbh & Co. Zahnpasta.
US4442119A (en) * 1980-07-07 1984-04-10 The Board Of Regents For The University Of Oklahoma Cyclopropyl analogs as estrogenic and anti-fertility agents
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4670428A (en) * 1982-02-01 1987-06-02 International Copper Research Association, Inc. Method for treating convulsions and epilepsy with organic copper compounds
US5015666A (en) * 1982-03-30 1991-05-14 Board of Reagents of the University of Oklahoma Triarylcyclopropanes as antiestrogens and antitumor agents
US4952607A (en) * 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4657928A (en) * 1982-05-27 1987-04-14 International Copper Research Association, Inc. Organic copper complexes as radioprotectants
USRE33403E (en) * 1982-06-03 1990-10-23 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
JPS5943375A (ja) * 1982-09-06 1984-03-10 Nippon Soken Inc 音源探査装置
US4512762A (en) * 1982-11-23 1985-04-23 The Beth Israel Hospital Association Method of treatment of atherosclerosis and a balloon catheter for same
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
US4758555A (en) * 1984-08-14 1988-07-19 International Copper Research Association Method for treating convulsions and epilepsy with organic copper compounds
US4757059A (en) * 1984-08-14 1988-07-12 International Copper Research Association Method for treating convulsions and epilepsy with organic copper compounds
US4758554A (en) * 1984-08-14 1988-07-19 International Copper Research Association Method for treating convulsions and epilepsy with organic copper compounds
US5226430A (en) * 1984-10-24 1993-07-13 The Beth Israel Hospital Method for angioplasty
IT1196390B (it) * 1984-12-28 1988-11-16 Consiglio Nazionale Ricerche Uso di derivati del tiofene nel trattamento dei tumori,composizioni farmaceutiche che li contengono e composti atti allo scopo
US5284763A (en) * 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US4826672A (en) * 1985-06-07 1989-05-02 President And Fellows Of Harvard College Astatinated organic compounds
DE3544663A1 (de) * 1985-12-13 1987-06-19 Schering Ag Thrombosebehandlung mit fibrinolytika und prostacyclinen
US5120535A (en) * 1986-11-26 1992-06-09 Oncogen Oncostatin M and novel compositions having anti-neoplastic activity
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5216021A (en) * 1986-08-28 1993-06-01 Sorenson John R J Analgesic method
US4999347A (en) * 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
EP0260066B1 (de) 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifenderivate
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
BR8806902A (pt) * 1987-04-16 1989-10-31 Christian Bindschaedler Processo para preparacao de um po de polimero insoluvel em agua que pode ser redispersado em uma fase liquida,po resultante e sua utilizacao
ES2044860T3 (es) * 1987-04-21 1994-01-16 Heumann Pharma Gmbh & Co Estables aductos con disolventes de z-1-(p-beta-di-metil-amino-etoxi-fenil)-1-(p-hidroxi-fenil)-2-fenil-but-1-eno.
SE8702254D0 (sv) 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
US4835002A (en) * 1987-07-10 1989-05-30 Wolf Peter A Microemulsions of oil in water and alcohol
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5221620A (en) * 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
US4929602A (en) * 1987-11-25 1990-05-29 Scripps Clinic And Research Foundation Method of inhibiting platelet dependent arterial thrombosis
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5468746A (en) 1988-07-29 1995-11-21 Zambon Group S.P.A. Compounds active on the cardiovascular system
US5328471A (en) * 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
DE68922497T2 (de) * 1988-08-24 1995-09-14 Marvin J Slepian Endoluminale dichtung mit bisdegradierbaren polymeren.
US5213580A (en) * 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
SE462364B (sv) * 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
US4886811A (en) * 1988-10-24 1989-12-12 Merrell Dow Pharmaceuticals Qunolyloxazole-2-ones useful as proteinkinase C inhibitors
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
CA2002011A1 (en) * 1988-11-14 1990-05-14 Anthony F. Purchio Normal human growth regulatory receptor for tgf-beta
US5268358A (en) * 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
US5304541A (en) * 1988-12-15 1994-04-19 Bristol-Myers Squibb Company Methods using novel chimeric transforming growth factor-β1/β2
CA2005120A1 (en) * 1988-12-15 1990-06-15 Anthony F. Purchio Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
US5380716A (en) * 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
DE3844247A1 (de) * 1988-12-29 1990-07-12 Minnesota Mining & Mfg Vorrichtung, insbesondere pflaster zum transdermalen verabreichen eines medikaments
US5284869A (en) * 1991-12-17 1994-02-08 Emil Bisaccia Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty
FR2645160B1 (de) * 1989-03-31 1992-10-02 Rhone Poulenc Chimie
US5364632A (en) * 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5026537A (en) * 1989-04-06 1991-06-25 Centocor, Inc. Methods for imaging atherosclerotic plaque
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5248764A (en) * 1989-06-16 1993-09-28 Merck Frosst Canada, Inc. Chelate derivatives of atrial natriuretic factor (ANF)
HU212760B (en) * 1989-06-20 1997-02-28 Denes Method and device for the apportion of chemical materials into the vein wall
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
US4990538A (en) * 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
US5145838A (en) * 1989-08-30 1992-09-08 Procyte Corporation Methods and compositions for healing ulcers
US5023237A (en) * 1989-08-30 1991-06-11 Procyte Corporation Methods and compositions for healing ulcers
IL95500A (en) 1989-09-11 1997-03-18 Matrix Pharma ANTI-PROLIFERATIVE COMPOSITIONS CONTAINING TGF-b PROTEIN IN A VISCOUS MATRIX AND THEIR USE
US5126348A (en) * 1989-09-26 1992-06-30 The University Of Colorado Foundation, Inc. Bioavailability enhancers
US5049132A (en) * 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US5108989A (en) * 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
JPH05507908A (ja) * 1990-04-06 1993-11-11 ウェイク　フォレスト　ユニバーシティー Ｈｓｐ７０によって処置する方法
US5166143A (en) * 1990-05-31 1992-11-24 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5401730A (en) 1990-07-06 1995-03-28 The Hope Heart Institute Method for reducing platelet aggregation
US5189046A (en) * 1990-08-14 1993-02-23 Nova Pharmaceutical Corporation Protein kinase C modulators
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
CA2092996A1 (en) * 1990-10-01 1992-04-02 David Yang High affinity tamoxifen derivatives and uses thereof
US5219548A (en) * 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
US5238714A (en) * 1990-10-02 1993-08-24 Board Of Regents, The University Of Texas System Efficient microcapsule preparation and method of use
US5053033A (en) * 1990-10-10 1991-10-01 Boston Advanced Technologies, Inc. Inhibition of restenosis by ultraviolet radiation
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
EP0557418B1 (de) * 1990-11-16 2000-06-28 Celtrix Pharmaceuticals, Inc. Beta-type ähnlicher transformierender wachstumfaktor
WO1992011872A1 (en) * 1991-01-03 1992-07-23 The Salk Institute For Biological Studies Mitotoxin for treatment of vascular injury
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
CA2108569A1 (en) * 1991-04-17 1992-10-18 H. Edward Conrad Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
IT1247527B (it) * 1991-04-24 1994-12-17 Medea Res Srl Agente antiarteriosclerotico, sua preparazione ed uso
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
GB9111439D0 (en) * 1991-05-28 1991-07-17 Thrombosis Res Inst Inhibition of vascular smooth muscle cell proliferation
US5213576A (en) * 1991-06-11 1993-05-25 Cordis Corporation Therapeutic porous balloon catheter
TW257762B (de) * 1991-06-14 1995-09-21 Nippon Chemicals Pharmaceutical Co Ltd
US5229495A (en) 1991-06-18 1993-07-20 Ludwig Institute For Cancer Research Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US5216126A (en) * 1991-06-19 1993-06-01 Genentech, Inc. Receptor polypeptides and their production and uses
US5185260A (en) * 1991-08-29 1993-02-09 The United States Of America As Represented By The United States Department Of Energy Method for distinguishing normal and transformed cells using G1 kinase inhibitors
AU2919392A (en) * 1991-10-23 1993-05-21 General Hospital Corporation, The Laser-based inhibition of smooth muscle cell hyperproliferation
WO1993009228A1 (en) * 1991-10-31 1993-05-13 Whitehead Institute For Biomedical Research TGF-β TYPE RECEPTOR cDNAS AND USES THEREFOR
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
AU678760B2 (en) * 1991-11-11 1997-06-12 Trustees Of The University Of Pennsylvania, The Methods of inhibiting restenosis
US5304325A (en) * 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
AU670770B2 (en) * 1991-12-04 1996-08-01 La Jolla Cancer Research Foundation Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
US5238950A (en) * 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
CA2125888C (en) * 1992-01-06 2002-08-27 Harry B. Demopoulos Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty
ES2100520T3 (es) 1992-01-17 1997-06-16 Daiichi Seiyaku Co Inhibidor de re-estenosis despues de la arterioplastia coronaria percutanea.
WO1993013752A1 (en) * 1992-01-21 1993-07-22 Sri International Improved process for preparing micronized polypeptide drugs
US5280109A (en) * 1992-01-27 1994-01-18 Ludwig Institute For Cancer Research Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2
US5444164A (en) 1992-02-05 1995-08-22 Bristol-Myers Squibb Company TGF-β induced gene
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5460807A (en) * 1992-08-19 1995-10-24 Merrell Dow Pharmaceuticals Inc. Antiproliferative oligomers
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤
EP0752885B1 (de) * 1992-09-25 2003-07-09 Neorx Corporation Therapeutischer inhibitor der vaskulären glatten muskelzellen
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
EP0666752A4 (de) * 1992-10-16 1996-09-11 Smithkline Beecham Corp Therapeutische mikroemulsionen.
AU679013B2 (en) * 1992-10-16 1997-06-19 Ibah, Inc. Convertible microemulsion formulations
ES2128441T3 (es) * 1992-10-27 1999-05-16 Nippon Kayaku Kk Empleo de toremifeno para tratar sle.
GB2273873A (en) * 1992-12-23 1994-07-06 Univ Sheffield Treatment of psoriasis
US5354774A (en) * 1992-12-24 1994-10-11 Yale University Inhibition of smooth muscle cell proliferation by 8-methoxypsoralen photoactivated by visible light
US5420243A (en) 1993-01-26 1995-05-30 Celtrix Pharmaceuticals, Inc. Biologically active TGF-β2 peptides
US5358844A (en) 1993-02-18 1994-10-25 Brigham And Women's Hospital, Inc. Preservation of blood platelets
US5308862A (en) 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US6197789B1 (en) * 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
CA2162586C (en) * 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5445941A (en) 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5354801A (en) * 1993-08-12 1994-10-11 Cytec Technology Corp. Process for producing small polymer phase droplet microemulsions by multistep aqueous phase addition
US5441947A (en) * 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5461065A (en) 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
US5482950A (en) 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US5418252A (en) * 1993-10-15 1995-05-23 Eli Lilly And Company Method for inhibiting cartilage degradation
US5457116A (en) 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
UA32427C2 (uk) 1993-10-15 2000-12-15 Елі Ліллі Енд Компані Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
US5457113A (en) 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5411988A (en) 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
US5480904A (en) 1993-10-28 1996-01-02 Eli Lilly And Company Methods for inhibiting uterine fibrosis
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5492927A (en) 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5451590A (en) 1993-12-21 1995-09-19 Eli Lilly & Co. Methods of inhibiting sexual precocity
US5447941A (en) 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5446053A (en) 1993-12-21 1995-08-29 Eli Lilly And Company Methods of inhibiting dysfunctional uterine bleeding
US5439931A (en) * 1993-12-21 1995-08-08 Eli Lilly And Company Method for increasing libido in post-menopausal women
US5462950A (en) 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5439923A (en) * 1993-12-21 1995-08-08 Eli Lilly And Company Method of inhibiting seborrhea and acne
US5441966A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
US5441965A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5461064A (en) 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5389670A (en) * 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5451589A (en) 1993-12-21 1995-09-19 Eli Lilly And Company Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5462949A (en) 1993-12-21 1995-10-31 Eli Lilly And Company Methods of inhibiting fertility in women
US5407955A (en) 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5455275A (en) 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5484798A (en) 1994-09-20 1996-01-16 Eli Lilly And Company Benzothiopene compounds, compositions, and method of inhibiting restenosis
US7501441B1 (en) 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies

Also Published As

Publication number Publication date
EP0710116A1 (de) 1996-05-08
CA2162586A1 (en) 1994-11-24
CA2162586C (en) 2006-01-03
JP2007084570A (ja) 2007-04-05
US5599844A (en) 1997-02-04
US5773479A (en) 1998-06-30
WO1994026303A1 (en) 1994-11-24
US5847007A (en) 1998-12-08
EP0710116B1 (de) 2008-09-03
JPH08510451A (ja) 1996-11-05
ATE406909T1 (de) 2008-09-15
US5945456A (en) 1999-08-31
US5472985A (en) 1995-12-05
US5545569A (en) 1996-08-13
EP0710116A4 (de) 1998-06-03
US6166090A (en) 2000-12-26

Similar Documents

Publication Publication Date Title
DE69435137D1 (de) Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
DK189886A (da) Roerformet proteseartikel
ATE193443T1 (de) Verwendung eines imidazols zur herstellung eines medikamentes zur behandlung der arteriosklerose
NO960899D0 (no) Fremgangsmåte for regulering av gastrointestinal motilitet
CA2162587A1 (en) Therapeutic inhibitor of vascular smooth muscle cells
ATE361669T1 (de) Zusammensetzungen zur behandlung vaskulärer verletzungen
DE68921918T2 (de) Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten.
DE69527847T2 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
ATE438361T1 (de) Stent beschichtet mit dna
DE69333413D1 (de) 5-ht2-antagonisten in der behandlung venöser zustände
ATE100716T1 (de) Verwendung von ace-inhibitoren gegen neointimabildung nach gefaessverletzung.
DE69805199D1 (de) Desferri-exochelin zur behandlung von atherosclerose und gefässbeschädigung durch verhinderung der proliferation von glatten muskelzellen
ES2174144T3 (es) Anticuerpos contra el factor de crecimiento derivado de plaquetas en el tratamiento de la reestenosis.
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
MX9709908A (es) Compuestos cetoheterociclicos, uso de los mismos y composiciones que los contienen.
ATE283063T1 (de) Allogene und xenogene transplantation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition